WO2006055981A3 - Use of cutured three-dimensional tissue for treating congestive heart failure - Google Patents

Use of cutured three-dimensional tissue for treating congestive heart failure Download PDF

Info

Publication number
WO2006055981A3
WO2006055981A3 PCT/US2005/042698 US2005042698W WO2006055981A3 WO 2006055981 A3 WO2006055981 A3 WO 2006055981A3 US 2005042698 W US2005042698 W US 2005042698W WO 2006055981 A3 WO2006055981 A3 WO 2006055981A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
congestive heart
cutured
dimensional tissue
treating congestive
Prior art date
Application number
PCT/US2005/042698
Other languages
French (fr)
Other versions
WO2006055981A2 (en
Inventor
Michael Siani-Rose
Robert S Kellar
Gail K Naughton
Stuart K Williams
Original Assignee
Theregen Inc
Michael Siani-Rose
Robert S Kellar
Gail K Naughton
Stuart K Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theregen Inc, Michael Siani-Rose, Robert S Kellar, Gail K Naughton, Stuart K Williams filed Critical Theregen Inc
Priority to AU2005306270A priority Critical patent/AU2005306270A1/en
Priority to AT05849967T priority patent/ATE500855T1/en
Priority to DE602005026866T priority patent/DE602005026866D1/en
Priority to EP05849967A priority patent/EP1838840B1/en
Priority to JP2007543510A priority patent/JP2008520748A/en
Publication of WO2006055981A2 publication Critical patent/WO2006055981A2/en
Publication of WO2006055981A3 publication Critical patent/WO2006055981A3/en
Priority to HK08103538.5A priority patent/HK1109783A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3826—Muscle cells, e.g. smooth muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3873—Muscle tissue, e.g. sphincter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents

Abstract

Methods for treating congestive heart failure using cultured three-dimensional tissue are provided herein.
PCT/US2005/042698 2004-11-22 2005-11-22 Use of cutured three-dimensional tissue for treating congestive heart failure WO2006055981A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2005306270A AU2005306270A1 (en) 2004-11-22 2005-11-22 Use of cutured three-dimensional tissue for treating congestive heart failure
AT05849967T ATE500855T1 (en) 2004-11-22 2005-11-22 USE OF THREE-DIMENSIONAL CULTURED TISSUE TO TREAT CONGESTIVE HEART FAILURE
DE602005026866T DE602005026866D1 (en) 2004-11-22 2005-11-22 USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE
EP05849967A EP1838840B1 (en) 2004-11-22 2005-11-22 Use of cultured three-dimensional tissue for treating congestive heart failure
JP2007543510A JP2008520748A (en) 2004-11-22 2005-11-22 Use of cultured three-dimensional tissue for the treatment of congestive heart failure
HK08103538.5A HK1109783A1 (en) 2004-11-22 2008-03-31 Use of cultured three-dimensional tissue for treating congestive heart failure

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63024304P 2004-11-22 2004-11-22
US60/630,243 2004-11-22
US69205405P 2005-06-17 2005-06-17
US60/692,054 2005-06-17

Publications (2)

Publication Number Publication Date
WO2006055981A2 WO2006055981A2 (en) 2006-05-26
WO2006055981A3 true WO2006055981A3 (en) 2006-07-27

Family

ID=36407890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/042698 WO2006055981A2 (en) 2004-11-22 2005-11-22 Use of cutured three-dimensional tissue for treating congestive heart failure

Country Status (8)

Country Link
US (6) US20060140916A1 (en)
EP (1) EP1838840B1 (en)
JP (2) JP2008520748A (en)
AT (1) ATE500855T1 (en)
AU (1) AU2005306270A1 (en)
DE (1) DE602005026866D1 (en)
HK (1) HK1109783A1 (en)
WO (1) WO2006055981A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007954A1 (en) 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
US20080226604A9 (en) * 2005-06-17 2008-09-18 Theregen Company Methods for treating ischemic tissue
ATE550423T1 (en) * 2004-08-30 2012-04-15 Theregen Inc THREE-DIMENSIONAL CULTIVATED TISSUES AND THEIR USE
EP1838840B1 (en) * 2004-11-22 2011-03-09 Theregen, Inc. Use of cultured three-dimensional tissue for treating congestive heart failure
US11224635B2 (en) 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
US8983570B2 (en) * 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
KR101610985B1 (en) 2008-11-14 2016-04-08 히스토젠, 인코포레이티드 Extracellular matrix compositions for the treatment of cancer
JP4815496B2 (en) * 2009-01-26 2011-11-16 エンパイア テクノロジー ディベロップメント エルエルシー Method for producing a three-dimensional product having a nanoporous surface
EP2226080A1 (en) * 2009-03-05 2010-09-08 Universiteit Maastricht Antagonistic peptides for frizzled-1 and frizzled-2
WO2010118352A1 (en) 2009-04-09 2010-10-14 Arizona Board Of Reagents On Behalf Of The University Of Arizona Cellular seeding and co-culture of a three dimensional fibroblast construct
SG186837A1 (en) 2010-03-01 2013-02-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve and methods associated therewith
AU2011276503B2 (en) 2010-06-28 2015-09-17 Colibri Heart Value LLC Method and apparatus for the endoluminal delivery of intravascular devices
TW201219573A (en) * 2010-09-22 2012-05-16 Ct Hospitalier Universitaire Vaudois Anti-fibrotic response provided by fetal cells to implants and delivery systems
SG10201601962WA (en) 2010-12-14 2016-04-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets
US9597436B2 (en) 2012-09-21 2017-03-21 Osaka University Advanced heart failure treatment material as myocardial/cardiovascular regeneration device
WO2015031110A2 (en) * 2013-08-27 2015-03-05 The Regents Of The University Of California Combination therapy to promote wound healing
GB201322869D0 (en) 2013-12-23 2014-02-12 Ucl Business Plc Therapeutic agents and delivery with microspheres
DE102014207153A1 (en) * 2014-04-14 2015-10-15 Rabea Hinkel AAV vectors for vascular gene therapy in coronary heart disease and peripheral ischemia
US11890395B2 (en) 2017-06-16 2024-02-06 Avery Therapeutics, Inc. Three dimensional tissue compositions and methods of use
WO2019051476A1 (en) 2017-09-11 2019-03-14 Incubar, LLC Conduit vascular implant sealing device for reducing endoleak

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US20030003089A1 (en) * 2001-05-11 2003-01-02 Akins Robert E. Tissue engineered cardiac constructs
US20030007954A1 (en) * 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
WO2004074457A2 (en) * 2003-02-20 2004-09-02 Macropore Biosurgery, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376118A (en) * 1989-05-10 1994-12-27 United States Surgical Corporation Support material for cell impregnation
GB9422389D0 (en) * 1994-11-05 1995-01-04 Int Computers Ltd Authenticating access control for sensitive functions
US5667528A (en) * 1995-11-22 1997-09-16 United States Surgical Corporation Braided suture surgical incision member attachment
US6214618B1 (en) * 1998-04-07 2001-04-10 Solohill Engineering, Inc. Microcarrier beads having a styrene copolymer core and a covalently linked tri-methylamine exterior
EP1102567B1 (en) * 1998-07-13 2004-11-10 Acorn Cardiovascular, Inc. Cardiac disease treatment device
US6730016B1 (en) * 2000-06-12 2004-05-04 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6719970B1 (en) * 2000-07-10 2004-04-13 Alkermes Controlled Therapeutics, Inc. Method of generating cartilage
US20040242469A1 (en) * 2002-05-13 2004-12-02 Lee Richard T. Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
JP2004075547A (en) * 2002-08-09 2004-03-11 Jms Co Ltd Composition for anagenesis
US20080226604A9 (en) * 2005-06-17 2008-09-18 Theregen Company Methods for treating ischemic tissue
ATE550423T1 (en) * 2004-08-30 2012-04-15 Theregen Inc THREE-DIMENSIONAL CULTIVATED TISSUES AND THEIR USE
EP1838840B1 (en) * 2004-11-22 2011-03-09 Theregen, Inc. Use of cultured three-dimensional tissue for treating congestive heart failure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US20030007954A1 (en) * 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
US20030003089A1 (en) * 2001-05-11 2003-01-02 Akins Robert E. Tissue engineered cardiac constructs
WO2004074457A2 (en) * 2003-02-20 2004-09-02 Macropore Biosurgery, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Also Published As

Publication number Publication date
HK1109783A1 (en) 2008-06-20
JP2008520748A (en) 2008-06-19
AU2005306270A1 (en) 2006-05-26
US20140271574A1 (en) 2014-09-18
EP1838840A2 (en) 2007-10-03
ATE500855T1 (en) 2011-03-15
US20090317482A1 (en) 2009-12-24
US20060140916A1 (en) 2006-06-29
EP1838840B1 (en) 2011-03-09
JP2012211175A (en) 2012-11-01
US20130064798A1 (en) 2013-03-14
US20110212068A1 (en) 2011-09-01
DE602005026866D1 (en) 2011-04-21
US20160256497A1 (en) 2016-09-08
WO2006055981A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
WO2006055981A3 (en) Use of cutured three-dimensional tissue for treating congestive heart failure
EP2197270B8 (en) Placental tissue grafts and improved methods of preparing and using the same
WO2005113747A3 (en) Multicellular tissue and organ culture systems
WO2007075326A3 (en) Methods of using cd40 binding agents
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
WO2006023651A3 (en) Extended treatment of multiple sclerosis
EP1784526A4 (en) An electromagnetically controlled tissue cavity distending system
WO2005107848A8 (en) Method for dermatological treatment using chromophores
WO2008091835A3 (en) Implantable medical endoprostheses
WO2006127900A3 (en) Tl1a in the treatment of disease
WO2006105458A8 (en) Method of optimizing mechanical heart rate during delivery of coupled or paired pacing
AU2005316238B2 (en) Cancer treatment method
WO2008027600A3 (en) Imatinib compositions
EP2091480A4 (en) System for the treatment of heart tissue
HU0401385D0 (en) Tissue cultivating method for culturing skin cells
EP1692513A4 (en) Diagnostic methods for congestive heart failure
WO2005077018A3 (en) Methods of treating skin disorders
ZA200703959B (en) Methods of using PDE V inhibitors for the treatment of congestive heart failure
WO2008058111A3 (en) Methods of preparing halohydroxypropyltrialkylammonium halides
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
AU2004907262A0 (en) Methods of treatment
AU2004907263A0 (en) Methods of treatment
AU2004900216A0 (en) Combined stimulation for auditory prosthesis
AU2004904932A0 (en) Method for defining cardiac time intervals
AU2004902857A0 (en) Tele-robotically controlled distributed isolation chamber for use in tissue engineering

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005849967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007543510

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005306270

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005306270

Country of ref document: AU

Date of ref document: 20051122

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005306270

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005849967

Country of ref document: EP